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Abstract Epidemiological studies show that atrial fibrilla-
tion (AF) is associated with a doubling of mortality, even
after adjustment for confounders. AF can be asymptomatic,
but this does not decrease the thromboembolic risk of the
patient. Office ECGs, occasional 24-h Holter recordings
and long-term ECG event recording might not be sensitive
and accurate enough in patients with AF, especially in those
with paroxysmal episodes. In one study, 7 days of
continuous monitoring with event recorders detected
paroxysmal AF in 20 of 65 patients with a previous
negative 24-h Holter recording. Over the last decade,
enormous improvements have been made in the technology
of implantable devices, which can now store significant
information regarding heart rhythm. The first subcutaneous
implantable monitor (Reveal XT, Medtronic) was validated
for continuous AF monitoring by the XPECT study. The
dedicated AF detection algorithm uses irregularity and
incoherence of R–R intervals to identify and classify
patterns in ventricular conduction. Its sensitivity in identi-
fying patients with AF is >96%. Numerous clinical data
from continuous monitoring of AF have recently been
published. The first applications of this technology have
been in the field of surgical and catheter AF ablation. With
regard to cryptogenic stroke, an international randomized
trial is ongoing to compare standard care with standard care
plus the implantable cardiac monitor for AF detection in
patients discharged with the diagnosis of cryptogenic
stroke: the Crystal AF trial. Continuous AF monitoring
provides an optimal picture of daily AF burden, both
symptomatic and asymptomatic. Implantable cardiac mon-
itors have high sensitivity, enable better assessment of
therapy success and may guide further AF therapy.
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1 Introduction
Almost 1–2% of the general population suffers from atrial
fibrillation (AF), and the prevalence is expected to double
or triple within the next two to three decades, both in
Europe and in the USA [1–4]. Epidemiological observa-
tions suggest that AF is associated with a doubling of
mortality, even after adjustment for confounders [2, 5].
Moreover, AF is the single most important risk factor for
ischemic stroke [4]. Therapeutic strategies are aimed at
restoring sinus rhythm, controlling the ventricular rate,
preventing thromboembolism and minimizing symptoms.
On the other hand, AF can be asymptomatic, but this
does not decrease the thromboembolic risk of the patient
[6]. Absence of symptoms can even increase this risk if
objective information on AF status is lacking, since
therapeutic decisions are usually based on both the absence
of clinical symptoms and documentation of sinus rhythm.
Office ECGs, occasional 24-h Holter recordings and
long-term ECG event recording are the monitoring strate-
gies usually adopted, but they might not be sensitive and
accurate enough in patients with AF, especially in those
with paroxysmal episodes [7, 8]. Considerable technolog-
ical advances have been made in the field of 30-day event
recorders [9]; however, the use of these devices should be
limited to highly compliant patients with frequent symp-
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criteria, which have also been suggested by recent guide-
lines on syncope, make external and implantable monitors
complementary [10]. Remote monitoring may also play a
role in heart failure (HF) patients and may help to detect
acute HF decompensation before the onset of symptoms.
Appropriate early intervention in these patients may reduce
hospitalizations and costs [11]. The diagnostic yield of
intermittent monitoring methods is limited and is clearly
related to the duration of monitoring. Depending on the
specific external monitoring method, sensitivity lies
between 31.3% and 71.0%, whereas the negative predictive
value (NPV) ranges between 21.5% and 64.6% [7, 8]
(Table 1).
Continuous monitoring of AF is possible through the
diagnostics of implantable dual-chamber pacemakers, dual-
chamber ICDs or implantable loop recorders (ILR). Given
the limitations inherent in intermittent monitoring, accurate
quantitative assessment of the Paroxysmal (P) AF burden
can only be achieved by using continuous cardiac rhythm
monitoring.
2 Assessment of symptomatic and asymptomatic AF
While AF can be associated with typical symptoms such as
palpitations, dyspnea, dizziness and syncope, a consider-
able proportion of patients remain asymptomatic. In
addition, symptomatic patients can also have asymptomatic
episodes; on the other hand, symptoms suggestive of AF
may sometimes not correspond to AF on the ECG. This
means that relying on symptoms to drive therapies for AF
can be very misleading. The advent of diagnostic features
for automatic AF detection, regardless of symptoms, has
further evidenced the burden of asymptomatic AF in the
general population suffering from this arrhythmia.
This issue has profound implications for the precise
definition of therapeutic success or endpoint of pharmaco-
logical prevention, cardioversion and ablation in the
management of AF. Thus, the low reliability of patients’
symptoms and the limitations of intermittent AF monitoring
strategies have dramatically increased the difficulty of
decisions regarding patients assumed to be AF-free. The
same issue affects the comparison of different therapeutic
approaches in clinical trials when symptoms and/or inter-
mittent methods of AF monitoring are used. Intuitively, the
results of such comparisons are dependent upon the method
of assessment and the population studied; that longer
periods of continuous monitoring would increase the
detection of asymptomatic AF is supported by clinical
studies.
Studies using only electrocardiogram (ECG) recordings
during clinic visits have found a 5%–20% prevalence of
asymptomatic AF in unselected patient groups [12, 13], but
Holter monitoring and event recorders have been seen to
increase the diagnostic yield for asymptomatic AF [14]. In
one study, 7 days of continuous monitoring with event
recorders detected paroxysmal AF in 20 of 65 patients with
a previous negative 24-h Holter recording [15]. Similarly,
Jabaudon et al. [16] showed that the longer we monitor
patients who have had a stroke, the more AF we find. In the
Prevention of Atrial Fibrillation After Cardioversion
(PAFAC) trial [17], about 70% of AF episodes detected
by transtelephonic transmission were asymptomatic. In
patients with previously documented paroxysmal AF,
sustained asymptomatic AF may be even more frequent
than symptomatic AF. Thus, the high incidence of stroke
in the rhythm-control arm of trials such as the AFFIRM
study may be related to the withdrawal of anticoagulation
therapy for patients believed to be in sinus rhythm [6].
Moreover, there is a lack of correlation among AF
symptoms, heart rate variation at the onset of AF, episode
duration, concomitant heart disease and antiarrhythmic drug
treatment [18, 19].
It is probable that the main determinant of symptoms is
the subjective perception of each patient, and this may
differ markedly among patients, making assessment unre-
liable. Patients may perceive AF-like symptoms in the
Table 1 AF monitoring options
Technology Storage Continuous Electrodes Comments
Symptoms None Yes None Only symptomatic events
ECG <1 min Yes 10 on skin
Holter 24–48 h Yes 3 on skin
Event recorder 7–28 days No 3 on skin Only symptomatic events
Transtelephonic ECG monitoring min/day No On skin Discontinuous
External loop recorder 7–28 days Yes On wrist or 2–3 on skin
Mobile cardiac outpatient monitoring Continuous, (<28 days) Yes 3 on skin Direct transmission
Implantable cardiac monitor Continuous Yes Under skin Implanted
Pacemaker, ICD Continuous Yes Implanted Implanted, PM/ICD pt.
228 J Interv Card Electrophysiol (2011) 32:227–232absence of arrhythmia. As a consequence, “time to first
symptomatic AF recurrence” is not an appropriate endpoint,
as it assumes that AF recurrences are random and AF is
symptomatic.
3 Ischemic stroke and continuous AF monitoring
Over the last decade, enormous improvements have been
made in the technology of implantable devices, which can
now store significant information regarding heart rhythm,
and numerous clinical data on the continuous monitoring of
AF have recently been published. This technology now
enables in vivo patterns of human AF to be reconstructed,
allowing a novel insight into the natural history and
pathophysiology of this arrhythmia over a long period
[20]. It can show both the progression of the disease from
the paroxysmal to the persistent form and the success of
treatment.
The correlation between the presence of atrial tachyar-
rhythmias during chronic monitoring and clinical outcomes
was first evaluated in the MOST trial [21] in a subgroup of
312 patients receiving pacemakers for sinus node dysfunc-
tion. The presence of atrial high rate episodes (≥220 beats/
min and longer than 5 min) was found to be an independent
predictor of total mortality, as well as death or nonfatal
stroke. This does not mean that 5 min of AF is dangerous;
the authors did not perform any analysis to correlate the
duration of the episodes with the clinical events. This
threshold was the result of a technical compromise in order
to exclude artifacts and store only atrial arrhythmias.
Capucci et al. [22] reported that patients with device-
detected AF recurrences longer than 1 day had a 3.1-fold
higher risk of embolism than patients without, or with
shorter, AF recurrences, a finding that indicates that AF
recurrences longer than 1 day are independently associated
with arterial embolism. Similar findings were reported by
Botto et al. [8], who also showed that the duration of AF
per day should be considered in combination with the risk
factors for stroke, as summarized by the CHADS2 score.
AF episodes lasting more than 24 h can be dangerous in
patients with a score = 1, while this is not the case for
shorter episodes. However, Botto et al. did not analyze the
data in such a way as to establish a threshold of the daily
AF burden (hours in 1 day) above which danger is incurred;
rather, they only analyzed events in patients with AF lasting
more or less than 24 h.
The TRENDS study [23] tried to assess this threshold.
The TRENDS data suggest that AF burden ≥5.5 h on any
day in the last 30 days is associated with an approximate
doubling of the risk of thromboembolism compared with
zero AF burden, after controlling for clinical stroke risk
factors and antithrombotic use.
The multicenter, large-scale, ongoing IMPACT trial [24]
was designed to test the hypothesis that initiation and
withdrawal of oral anticoagulant therapy guided by contin-
uous monitoring improve clinical outcomes by reducing the
combined rate of stroke, systemic embolism and major
bleeding more effectively than conventional clinical man-
agement. The early detection of AF generates an automatic
alert to initiate anticoagulation based on patient-specific
stroke risk stratification. Subsequently, freedom from AF
for predefined periods prompts withdrawal of anticoagula-
tion in order to avoid bleeding.
4 Subcutaneous leadless AF monitoring
Recently, the first subcutaneous ILR was validated for
continuous AF monitoring by the XPECT study [25]. The
ICM (Reveal XT; Medtronic Inc.) is equipped with a new AF
detection algorithm that is designed to detect the presence of
AF episodes and to quantify the AF burden. In addition, the
ICM features detection algorithms for bradyarrhythmias and
ventricular tachyarrhythmias. Physiological sinus rhythm and
AF each have a unique R–R interval pattern. The dedicated
AF detection algorithm uses irregularity and incoherence of
R–R intervals to identify and classify patterns in ventricular
conduction. The R–R intervals are analyzed within each 2-
min period, and the difference in duration between consec-
utive R–R intervals (ΔR–R) is calculated.
Subsequently, the variability of these ΔR–R intervals is
calculated, much as a Lorenz plot is constructed. When the
R–R intervals within the 2-min period show a certain
pattern of irregularity, the heart rhythm in this period is
classified as AF. If R–R intervals are regular, with some
sinus node modulations, the 2-min period is defined as
normal sinus rhythm (Fig. 1). The ICM can store up to
49.5 min of recorded ECG, which is allocated to 27 min of
automatically activated events and 22.5 min of patient-
activated events. In addition, the ICM has an episode log
that can catalogue 30 automatically detected AF episodes
and up to ten patient-activated episodes. When the memory
is full, an additional episode will overwrite the oldest stored
episode. The devices can be implanted subcutaneously
under local anesthesia.
The XPECT study compared the diagnostic data stored
automatically by the ICM with the corresponding visual
inspection of the ECG traces carried out by the investigators.
The study showed that the overall accuracy of the ICM in
measuring AF burden was 98.5%, with a Pearson correlation
coefficient of r=0.976 between the daily burden automati-
cally calculated by the device and that measured by the
investigators. The sensitivity in identifying patients with any
AF was 96.1% and specificity 85.4%. The corresponding
PPV and NPV were 79.3% and 97.4%, respectively.
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and future perspectives
The first experience of using a permanently implantable
ICM, the Reveal XT (Medtronic, Inc.), following surgical
therapy for AF was reported by Hanke et al. [26]. The aims
of the study were to accurately evaluate the evolution of
heart rhythm after surgical ablation therapy and to examine
potential discrepancies in identifying post-procedural AF
recurrence by means of intra-patient comparison of two
different follow-up strategies: conventional 24-h Holter
monitoring (24HM) at prescheduled times and continuous
cardiac rhythm surveillance. Continuous heart rhythm
surveillance was much more accurate in detecting AF
recurrence after surgical ablation therapy. In addition, the
study provided strong evidence that the commonly used
intermittent follow-up strategy is significantly inferior to
full-disclosure heart rhythm observation with respect to AF
recurrence detection. Hanke et al. demonstrated that, even
when 24HM was performed quarterly, the level of correct
interpretation, in comparison with that of continuous heart
rhythm surveillance, was still unsatisfactory, sensitivity
being only 60%.
Pokushalov et al. [27] used the ILR for continuous AF
monitoring in 89 patients with symptomatic, drug-refractory,
longstanding persistent AF, who had undergone anatomic
ablationofthe areas ofganglionated plexi inthe leftatrium.In
29patients,asecondprocedureforcircumferential pulmonary
vein isolation wasperformed,and fiveofthemweresubjected
to a third circumferential ablation procedure. After a follow-
up of 16±7 months from last procedure, 53 (59.6%) of the 89
patients were in sinus rhythm, as documented by the ILR,
without antiarrhythmic drug therapy. The authors found that
the long-term success rate in patients who underwent a single
ablation procedure involving ganglionated plexi ablation
alone was 38.2% over a follow-up of 24±3 months. Using
the same monitoring technique, the same group [28]s h o w e d
that ablation of the areas of the ganglionated plexi in 56
patients with paroxysmal AF yielded a success rate of 71%
over a 12-month period.
AF Sinus rhythm
Normal variations Irregular irregularity
Fig. 1 R–R intervals are ana-
lyzed within each 2-min period,
and the difference in duration
between consecutive R–R inter-
vals (ΔR–R) is calculated. The
variability of ΔR-R intervals is
calculated in order to distinguish
sinus rhythm (left side) from
atrial fibrillation (right side)
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ECG at the onset of AF, as stored by the ICM
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Trend of daily AF burden from Cardiac Compass Fig. 2 This is an example from
the Cardiac Compass, the soft-
ware tool provided by the pro-
grammer to show the trend in
data during follow-up. The trend
in the daily AF burden shows
that paroxysmal AF is worsen-
ing over time, with longer and
longer episodes. The ECG strip
stored by Reveal XT shows the
onset of an AF episode
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ablation and post-ablation AF burden in patients with
paroxysmal or persistent AF [29]; ablation dramatically
and significantly reduced AF burden, and 62% of patients
were AF-free 9 months after the procedure. Similar
results were also obtained by Amellone et al. [30]a n d
Chun et al. [31] through continuous subcutaneous post-
ablation monitoring.
In the field of cryptogenic stroke, an international
randomized trial is ongoing to compare standard care (SC)
with SC plus the Reveal XT ICM for AF detection in
patients discharged with the diagnosis of cryptogenic
stroke: the Crystal AF trial [32].
For pharmaceutical companies, the use of continuous AF
monitoring in AF trials is particularly advantageous; as all
AF episodes will be registered, fewer patients will be
required and the effect of therapy will become apparent in a
shorter period of time. One of the first pilot studies was
performed by Arya et al., [33], who evaluated a new AF
drug (budiodarone) in pacemaker patients. A direct corre-
lation between AF burden and drug dosage was observed
and AF burden returned to baseline values during drug
washout.
In the future, any AF trial studying the effect of a rhythm
control intervention should consider continuous monitoring
as the elective tool for reliably measuring the effect of
therapy. Figure 2 shows an example of the trend in the daily
AF burden recorded by a Reveal XT (Medtronic) device
implanted in a patient with paroxysmal AF. The data clearly
show progression of the disease and the ECG allows
validation by the physician. This rigorous approach is also
confirmed in the Consensus Statement of the EHRA and
the German AFNET [34], according to which, with regard
to ECG-based outcomes, “To assess freedom from AF,
continuous ECG recording is the gold standard.”
6 Conclusions
Symptom-related or intermittent AF measurement in AF
trials is highly unreliable in the evaluation of a rhythm
control intervention. Continuous AF monitoring provides
an optimal picture of both symptomatic and asymptomatic
daily AF burden.
Implantable cardiac monitors have high sensitivity,
provide a better assessment of therapy success, and may
guide further AF therapy.
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